Friday, August 14, 2026
← Back to archivePolicy
Policy•KFF•Aug 13, 2026
Many Adults Are Unaware of the Abortion Pill’s Safety and Prevalence as Misleading Claims Link the Medication to Wastewater Contamination — The Monitor
background ▾
- •Public confidence in FDA's science-based decision-making on mifepristone is eroding (54% lack confidence), with partisan divides and post-COVID institutional trust deficits complicating the regulatory environment.
- •Anti-abortion groups are deploying discredited environmental contamination claims based on methodologically flawed research to achieve drug restriction objectives outside traditional regulatory channels.
- •Monitor FDA's formal response to the wastewater contamination allegations and whether environmental health criticisms of the preprint gain institutional traction with EPA and scientific bodies.
mifepristone
→ Read original articlePolicy•KFF•Aug 13, 2026
Prior Authorization Metrics Provide New Insights into Insurer Practices, but Gaps Remain
background ▾
- •CMS now mandates annual public reporting of prior authorization metrics (approval/denial rates, response times) for Medicare Advantage, Medicaid, and ACA Marketplace plans, representing a significant regulatory shift toward payer transparency
- •KFF analysis reveals challenges in interpreting aggregated metrics across diverse medical services and insurers, limiting the rule's intended goal of enabling consumer-driven plan selection
- •Watch for emerging policy refinements addressing data standardization, service-level granularity, and potential expansion of reporting requirements to commercial insurers and prescription drug prior authorization
Centers for Medicare and Medicaid ServicesKaiser Family Foundation
→ Read original articlePolicy•STAT News•Aug 14, 2026
How will legal challenges fare against CMS rule on gender-affirming care?
background ▾
- •CMS finalized a federal funding ban for pediatric gender-affirming medications and surgery under standard regulatory process, making it more legally defensible than prior administration actions that have been enjoined by courts
- •Legal experts note the unilateral revocation of coverage without Congressional directive may be unprecedented, with CMS relying on analogies (Hyde Amendment, sterilization restrictions) that experts say are not directly comparable
- •Lawsuits are expected imminently; Massachusetts AG has confirmed plans to challenge; mental health care remains covered and states may use their own Medicaid dollars, creating complex litigation over federal vs. state authority
Policy•STAT News•Aug 14, 2026
Opinion: MAHA and insurance companies both want to treat human bodies like cars
background ▾
- •Health insurance companies and White House officials are actively promoting wearable adoption using incentive-based models (discounts, rewards) similar to auto insurance telematics, despite evidence that auto telematics have not delivered promised consumer savings
- •FDA reclassified AI-enabled wearables in January to reduce regulatory burden, allowing non-diagnostic/non-therapeutic devices to bypass heavy medical device oversight
- •Major unanswered questions persist regarding privacy protections, data security, clinical utility of generated data, and whether cost savings will materialize or primarily benefit insurers
John HancockDiscovery LimitedUnitedHealthcare
→ Read original articlePolicy•STAT News•Aug 14, 2026
Two years after rules overhaul, have methadone clinics really changed?
background ▾
- •Regulatory changes mandating flexibility in take-home methadone and decoupling counseling from medication access are driving measurable improvements in patient retention (17% average increase) across early-adopting clinics.
- •Over 75% of OTPs have adopted at least some major regulatory changes, indicating significant industry compliance, though the survey covered only 10% of nationwide programs and may reflect selection bias toward progressive clinics.
- •Watch for: Sustained retention and clinical outcome data from larger, more representative clinic samples; state-level adoption variability; and whether the cultural shift toward patient-centered care persists as regulatory momentum fades.
CompDrugAmerican Association for the Treatment of Opioid Dependence (AATOD)National Association of Addiction Treatment Providersmethadone
→ Read original articleMarket Access
Market Access•Fierce Biotech•Aug 13, 2026
Pfizer’s former chemistry whiz debuts Khartis Therapeutics with $95M for thyroid eye disease pill
background ▾
- •Khartis is developing an oral, selective IGF-1R inhibitor for TED—a significant potential advantage over existing IV-infused therapies (Tepezza, Lumvoa) in a disease with real patient burden and safety tradeoffs.
- •Direct competitive threat: Sling Therapeutics' linsitinib has already posted positive Phase 2b/3 data and is in confirmatory Phase 3, putting Khartis roughly 2+ years behind in clinical development.
- •Watch for: Khartis' Q1 2027 trial initiation, ongoing Phase 3 results from linsitinib, and whether oral IGF-1R selectivity translates to meaningfully improved safety/durability versus IV competitors—determining which asset(s) ultimately capture market share in TED.
Khartis TherapeuticsAmgenViridian TherapeuticsTepezzaLumvoalinsitinib
→ Read original articleMarket Access•Fierce Biotech•Aug 13, 2026
PTC’s $211M bid wins Sangamo auction, teeing up ‘special opportunity’ to enter Fabry market
background ▾
- •PTC paid $111M upfront—4x the initial Astellas stalking horse bid of $25M—indicating intense competitive interest and confidence in ST-920's approval prospects
- •ST-920 has already submitted nonclinical and clinical modules in rolling review; PTC expects to complete filing in Q4 by submitting CMC package, positioning for accelerated approval decision
- •PTC's rationale centers on operational synergy (no significant build-out needed) rather than transformational pipeline addition, reducing execution risk
PTC TherapeuticsSangamo TherapeuticsAstellasisaralgagene civaparvovecST-920
→ Read original articleMarket Access•Fierce Biotech•Aug 13, 2026
Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decision
background ▾
- •Zealand monetizes a legacy economic interest in rusfertide ahead of FDA decision, freeing capital for high-priority obesity pipeline while maintaining 0.25% royalties on sales above $1.5B threshold
- •Rusfertide showing strong phase 3 efficacy (76.9% response rate) in polycythemia vera with potential to reduce/eliminate phlebotomy, but FDA approval outcome still pending in Q3 2024
- •Monitor FDA rusfertide decision Q3 2024 and subsequent commercial uptake; also track Zealand's petrelintide and survodutide progress as obesity programs are strategic priority for redeployed capital
Zealand PharmaTakedaProtagonist Therapeuticsrusfertidepetrelintidesurvodutide
→ Read original articleMarket Access•Fierce Biotech•Aug 13, 2026
Medtronic veteran Bill Shields crosses over to become CEO at valve disease startup
background ▾
- •Senior Medtronic structural heart executive with deep transcatheter device experience joins early-stage competitor, signaling confidence in AdapTR technology and tricuspid repair market potential
- •Versa securing increased Series C funding and advancing to U.S. feasibility study while competitors Abbott (TriClip) and Medtronic (Intrepid) have more mature programs
Versa VascularMedtronicAbbottAdapTRTriClipIntrepid TMTR/TTVR
→ Read original articleMarket Access•Fierce Biotech•Aug 13, 2026
After tasting IPO success, Hemab’s CEO seeks ‘flavor of a multi-product coagulation company’
background ▾
- •Hemab's stock tripled post-IPO ($18 to $53.48 by August) backed by strong investor demand and positive phase 2 data on lead programs targeting rare and underserved bleeding disorders
- •The company has three programs with recent clinical readouts (sutacimig phase 2, HMB-002 phase 2, HMB-003 pre-clinical) positioning it for potential phase 3 advancement and market differentiation in a niche therapeutic area
HemabsutacimigHMB-002HMB-003
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Aug 14, 2026
MapLight dims preclinical programs to make phase 3-ready schizophrenia drug shine brighter
background ▾
- •ML-007C-MA met primary endpoint in Zephyr phase 2 on twice-daily dosing with significant disease severity reductions, but once-daily dosing failed to meet efficacy threshold, narrowing the commercial profile versus competitors
- •MapLight is terminating investment in all preclinical programs (including promising ML-055 candidate) and culling the pipeline to focus capital exclusively on ML-007C-MA phase 3 execution and Vista ADP trial through 2028
- •Watch for FDA pre-phase 3 meeting outcomes (timing not specified) and whether MapLight can overcome the once-daily dosing limitation; competitive pressure from Cobenfy and other muscarinic agonists in development will determine market success
MapLight TherapeuticsBristol Myers SquibbML-007C-MAML-055Cobenfy
→ Read original articleClinical Trials•Fierce Biotech•Aug 13, 2026
PDS halts work on phase 3 cancer therapy to focus on colorectal contender
background ▾
- •Phase 3 trial discontinuation represents a significant setback for PDS0101 despite encouraging phase 2 OS data (39.3 months median), signaling confidence gap between early and late-stage evidence or commercial viability concerns.
- •PDS0301's 77.8% ORR in metastatic colorectal cancer (albeit in small n=9 cohort) is unusually strong and justifies resource reallocation, though lack of durability and OS data creates execution risk.
- •Monitor PDS0301 phase 2 expansion and partnership announcements for PDS0101; company's severe cash position ($5.6M) may force additional portfolio decisions or acquisition interest.
PDS BiotechnologyMerck (Keytruda)National Cancer InstituteVersamune HPVPDS0101PDS0301
→ Read original articleClinical Trials•Endpoints News•Aug 13, 2026
Ovid and Takeda's epilepsy drug gets new life at Perceptive-backed NewCo
background ▾
- •Failed Phase 3 epilepsy program is being resurrected through a newly formed entity with Perceptive Advisors backing, indicating continued belief in the asset despite clinical setbacks.
- •The revival strategy may involve protocol modifications or a different patient population, though specific details on how the candidate will differ from prior failed trials are not disclosed in this excerpt.
Ovid TherapeuticsTakeda PharmaceuticalPerceptive Advisors
→ Read original articleClinical Trials•Endpoints News•Aug 13, 2026
Taiho, Cullinan's lung cancer drug passes Phase 3 test, lining up Rybrevant contest
background ▾
- •Phase 3 readout demonstrates efficacy in front-line genetically-defined lung cancer, supporting regulatory filing potential
- •Direct competition with Rybrevant signals multiple treatment options emerging in next-generation EGFR inhibitor class
- •Detailed efficacy/safety data and regulatory submission timeline needed to assess competitive positioning
Taiho OncologyCullinan TherapeuticsAstraZenecaRybrevantTaiho/Cullinan EGFR inhibitor (INN not specified)
→ Read original article